^
    Back
    Association details:
    Biomarker:SDHB mutation
    Cancer:Gastrointestinal Stromal Tumor
    Drug:temozolomide (DNA synthesis inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    Clin Cancer Res
    Title:

    Establishment of Patient-derived Succinate Dehydrogenase-deficient Gastrointestinal Stromal Tumor Models For Predicting Therapeutic Response

    Published date:
    08/23/2021
    Excerpt:
    ...a cohort of SDH-mutant GIST patients treated with temozolomide (n=5) demonstrated a 40% objective response rate and 100% disease control rate suggesting that temozolomide represents a promising therapy for this subset of GIST.
    DOI:
    10.1158/1078-0432.CCR-21-2092